Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Videos|April 9, 2026
7 Endocrinology Headlines You Missed in March 2026
Author(s)Abigail Brooks, MA
Fact checked by: Ryan Livingston
March 2026 endocrinology updates include key FDA approvals, advances in diabetes and obesity therapies, and innovations in insulin delivery and rare disease care.
Advertisement
Advertisement
March brought a series of notable developments in endocrinology, with regulatory milestones and clinical trial advances continuing to reshape the treatment landscape across diabetes, obesity, and rare endocrine disorders. From first-in-class therapies to innovations in drug delivery, the month underscored a growing emphasis on improving both clinical outcomes and patient experience.
Related to this article
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
Advertisement
Advertisement